Scientists Think Psychedelics Could Treat Autism

For decades, the standard approach to Autism Spectrum Disorder has been damage control. Risperidone. Aripiprazole. Drugs that blunt the edges of irritability and aggression without touching the underlying architecture of the condition. The social communication problems persist. The cognitive rigidity persists. It’s a bandaid aid approach.

A new comprehensive review published in Progress in Neuro-Psychopharmacology and Biological Psychiatry challenges that framing entirely. The paper synthesises lots of evidence suggesting that serotonergic psychedelics, particularly psilocybin, LSD, and DMT, may engage the very neurobiological mechanisms disrupted in ASD. These include impaired neuroplasticity, dysregulated serotonin signalling, chronic neuroinflammation, and overly rigid predictive hierarchies in the brain.

The review’s core argument operates across three levels: molecular, circuit, and systems. At each level, psychedelics appear to engage mechanisms that are specifically disrupted in ASD.

One of the most compelling ideas in the paper is the concept of critical periods. During early development, the brain passes through windows of heightened plasticity when neural circuits are especially malleable in response to experience. Social learning, language acquisition, emotional regulation, these capacities depend on these windows remaining open long enough for the right inputs to shape the right circuits.

In ASD, there is growing evidence that these windows close prematurely. The brain locks in, early and rigid, before adequate learning has occurred. This is not a wiring fault. It is an ecological failure of timing.

Psychedelics, according to both preclinical data and the REBUS theoretical framework, can temporarily reopen these windows. In rodent studies, compounds including LSD, psilocybin, and MDMA restored juvenile-like plasticity in social reward circuits when administered in adulthood. The mechanism involves activation of the 5-HT2A receptor on deep-layer cortical pyramidal neurons, triggering a cascade: glutamate release, AMPA receptor activation, BDNF secretion, TrkB and mTOR signalling, dendritic growth and synaptogenesis.

Essentially, the brain is briefly returned to a state resembling its own developmental past.

The review documents the consistently elevated inflammatory tone in ASD brains, which results in excess reactive oxygen species and impaired synaptic pruning. This is not incidental. Chronic neuroinflammation actively suppresses long-term potentiation, reduces neurogenesis, and prevents plasticity.

Psychedelics address this through a mechanism called functional selectivity at the 5-HT2A receptor. Endogenous serotonin binding to 5-HT2A tends to activate pro-inflammatory signalling pathways. Psychedelic ligands appear to engaging anti-inflammatory signalling instead.

The REBUS (Relaxed Beliefs Under Psychedelics) model, developed by Carhart-Harris and Friston, offers a systems-level account of why psychedelics might be particularly relevant to ASD. The brain, in this framework, operates as a prediction machine, constantly generating top-down models of reality and testing them against incoming sensory data. ASD, the theory proposes, involves an overfitted version of this process, with top-down priors that are too rigid, too heavily weighted, and unable to update flexibly in response to ambiguous or social stimuli.

Psychedelics, via 5-HT2A activation on the neurons that encode these high-level priors, temporarily flatten the free-energy landscape. The dominant attractors loosen and the system becomes, briefly, more exploratory. The review describes this as an “afterglow period” of enhanced cognitive flexibility that follows the acute psychedelic experience. In simple terms, it’s a window in which entrenched patterns may be revised.

Almost all mechanistic evidence is preclinical or drawn from non-ASD populations. The one modern controlled trial, Danforth et al. (2018), used MDMA-assisted therapy in 12 autistic adults with social anxiety and found significant, sustained reductions in anxiety scores. It’s encouraging, but a small sample. The PSILAUT trial for psilocybin is currently ongoing, with results expected later in 2026.

ASD is one of the most diverse conditions in neuroscience. What disrupts one person’s serotonin system may look nothing like what disrupts another’s. Precision medicine approaches, using neuroimaging biomarkers, inflammatory markers, and receptor genetics, will be essential before any of this moves into clinical practice.

There are also safety concerns. Psychedelics amplify sensory and emotional experience, which may be particularly challenging for individuals who already experience sensory overwhelm.

But what the review offers is a coherent rationale for why this direction is worth pursuing.

The ASD brain is not a broken machine. It is a complex system that, under chronic stress, has adapted its architecture in ways that make sense ecologically even when they limit function socially. Restoring that system requires more than a single intervention. Psychedelics, in this framing, are not a cure. But they could be a catalyst that opens a window for healing.

Source: Low, Z.X.B. et al. (2026). Serotonergic psychedelics for Autism Spectrum Disorder: Neurobiological mechanisms and translational prospects. Progress in Neuro-Psychopharmacology and Biological Psychiatry.